2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

cell killing

" in MedChemExpress (MCE) Product Catalog:

167

Inhibitors & Agonists

2

Screening Libraries

4

Fluorescent Dyes

2

Biochemical Assay Reagents

16

Peptides

37

Inhibitory Antibodies

16

Natural
Products

13

Isotope-Labeled Compounds

1

Click Chemistry

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0667
    L-Asparagine
    5 Publications Verification

    (-)-Asparagine; Asn; Asparamide

    		 Endogenous Metabolite Apoptosis DNA/RNA Synthesis Inflammation/Immunology
    L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .
    L-Asparagine
  • HY-129046
    RNase A, Bovine pancreas
    5 Publications Verification

    Ribonuclease A; EC 4.6.1.18; RNase A

    		 Endonuclease DNA/RNA Synthesis Others
    RNase A (Bovine pancreatic RNase) is a widely used Endonuclease in DNA purification by specifically hydrolyzing cytosine or uracil residues of RNA. RNase A degrades the RNA in the RNA/DNA duplex. RNase A catalyses the breakdown of 3',5'-phosphodiester linkages of single stranded RNA. RNase A family members in organisms are tightly involved in various physiological and pathological processes including cell growth and development, proliferation, differentiation and migration. Dysregulation of RNase A activity or expression level is closely related to pancreatic, ovarian, bladder and thyroid cancer. RNase A has tumor cell-killing ability .
    RNase A, Bovine pancreas
  • HY-P99024
    Glofitamab
    1 Publications Verification

    RO7082859; RG-6026

    		 CD20 CD3 Inflammation/Immunology Cancer
    Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
    Glofitamab
  • HY-148026
    Sonrotoclax

    BGB 11417

    		 Bcl-2 Family Cancer
    Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .
    Sonrotoclax
  • HY-P99601
    Cevostamab

    BFCR 4350A; RG 6160; RO 7187797

    		 CD3 Neurological Disease Cancer
    Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
    Cevostamab
  • HY-W010342
    6-Aminonicotinamide
    Maximum Cited Publications
    17 Publications Verification

    		 NADPH Oxidase Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
    6-Aminonicotinamide
  • HY-14989
    SQ109
    4 Publications Verification

    NSC 722041

    		 Parasite Bacterial Antibiotic Infection
    SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM. SQ109, targets MmpL3, is an antitubercular agent.
    SQ109
  • HY-P99394
    Talquetamab
    1 Publications Verification

    JNJ-64407564

    		 CD3 Cancer
    Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
    Talquetamab
  • HY-162472
    XRD-0394

    		ATM/ATR DNA-PK Cancer
    XRD-0394 is a potent and orally active dual ATM and DNA-PKcs inhibitor with IC50s of 0.39 nM and 0.89 nM, respectively. XRD-0394 shows selectivity over other PIKK and PI3K family members. XRD-0394 significantly enhances tumor cell killing in vitro and in vivo under therapeutic ionizing radiation conditions. XRD-0394 can potentiate the effects of PARP and topoisomerase I inhibitors in vitro .
    XRD-0394
  • HY-P99011
    Cibisatamab
    2 Publications Verification

    		 CD3 Cancer
    Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
    Cibisatamab
  • HY-P99051
    Tinurilimab
    2 Publications Verification

    BAY 1834942

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
    Tinurilimab
  • HY-134582
    dCBP-1
    10+ Cited Publications

    		 PROTACs Epigenetic Reader Domain Cancer
    dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .
    dCBP-1
  • HY-156773
    STM3006
    2 Publications Verification

    		 Apoptosis METTL3 Cancer
    STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .
    STM3006
  • HY-P99521
    Vibecotamab

    XmAb14045

    		 CD3 Inflammation/Immunology Cancer
    Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
    Vibecotamab
  • HY-N0591
    Dehydrocostus Lactone
    2 Publications Verification

    (-)-Dehydrocostus lactone; Epiligulyl oxide

    		 Bacterial Apoptosis p38 MAPK NF-κB MAPKAPK2 (MK2) Akt NO Synthase Interleukin Related Caspase Infection Inflammation/Immunology Cancer
    Dehydrocostus Lactone ((-)-Dehydrocostus lactone) is a natural sesquiterpene that can be isolated from Saussurea lappa. Dehydrocostus Lactone has multiple activities such as anti-inflammatory, antibacterial, anti-tumor, and immunomodulatory effects. Dehydrocostus Lactone has an MIC of 2 µg/mL against Mycobacterium tuberculosis. Dehydrocostus Lactone can also inhibit the killing activity of cytotoxic T lymphocytes and induce apoptosis in tumor cells .
    Dehydrocostus Lactone
  • HY-175751
    LRK-4189

    		mTOR Cancer
    LRK-4189 is an orally active PIP4K2C (a regulator of mTOR complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .
    LRK-4189
  • HY-B0991
    Amoxapine
    4 Publications Verification

    CL-67772

    		 Bacterial Autophagy Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Amoxapine (CL-67772) is a norepinephrine reuptake blocker and a 5-HT2/5-HT3 antagonist. Amoxapine can be used for the research of depression. Amoxapine has antibacterial activity. Amoxapine can enhance the killing effect of macrophages on mycobacterium by inducing autophagy, while protecting the cells from death .
    Amoxapine
  • HY-P991731
    Alveltamig

    ZG006

    		 CD3 Notch Neurological Disease Cancer
    Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
    Alveltamig
  • HY-138936
    SSK1
    2 Publications Verification

    		 p38 MAPK Apoptosis Inflammation/Immunology
    SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted proagent attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis .
    SSK1
  • HY-N2877
    Annonacin
    1 Publications Verification

    		 Potassium Channel Sodium Channel Na+/K+ ATPase Calcium Channel Apoptosis Neurological Disease Cancer
    Annonacin is an acetylgenin that is toxic by inhibiting the pathway of the mitochondrial complex. Annonacin increases tau phosphorylation in R406W +/+ mice. Annonacin acts as an inhibitor of the sodium/potassium and sarcoplasmic reticulum (SERCA) ATPase pumps. Annonacin has significant killing effect on ovarian cancer cell, cervical cancer cell, breast cancer cell, bladder cancer cell and skin cancer cell. Annonacin induces apoptosis through Bax and Caspase-3-related pathways .
    Annonacin
  • HY-P990925
    Linclatamig

    BLYG8824A; RG6286

    		 CD3 Inflammation/Immunology
    Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and CD3. Linclatamig can bind to LY6G6D and CD3-positive T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in colorectal cancer research .
    Linclatamig
  • HY-P9983
    Lintuzumab

    SGN-33; HuM-195; GLK-33 Antibody

    		 Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs) Inflammation/Immunology
    Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
    Lintuzumab
  • HY-W017443
    L-Asparagine monohydrate
    5 Publications Verification

    		 Endogenous Metabolite Apoptosis DNA/RNA Synthesis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia .
    L-Asparagine monohydrate
  • HY-W145657
    Trehalose 6,6′-dimycolate

    Cord Factor

    		 Biochemical Assay Reagents Infection
    Trehalose 6,6'-dimycolate (Cord Factor) is trehalose 6,6'-dimycolate, a cell wall glycolipid of Mycobacterium tuberculosis, which can be used to simulate inflammation and granuloma induced by Mycobacterium tuberculosis (MTB) form. Trehalose 6,6′-dimycolate also protects Mycobacterium tuberculosis from macrophage-mediated killing, inhibits efficient antigen presentation, and reduces the development of protective T cell responses .
    Trehalose 6,6′-dimycolate
  • HY-N2123
    Neoliquiritin
    1 Publications Verification

    		 Caspase Neurological Disease Cancer
    Neoliquiritin is a flavonoid and flavanone-derived cytotoxic agent with anticancer activity and neuroprotective effects. Neoliquiritin exhibits excellent tumor specificity, exerting a more pronounced killing effect on cancer cells compared with normal oral cells. Neoliquiritin also exerts neuroprotective effects by inhibiting ATP depletion and the elevation of caspase 3/7 activity. Widely present in the roots of Glycyrrhiza uralensis, Glycyrrhiza inflata and Glycyrrhiza glabra, Neoliquiritin can be applied to studies on human oral squamous cell carcinoma, leukemia, Parkinson's disease and other conditions .
    Neoliquiritin
  • HY-P99157
    Omburtamab

    		CD276/B7-H3 Cancer
    Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
    Omburtamab
  • HY-15045
    INO-1001
    2 Publications Verification

    		 PARP Cancer
    INO-1001 is a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death . INO-1001 has anti-tumor effects .
    INO-1001
  • HY-132192
    PD-1/PD-L1-IN-9
    2 Publications Verification

    		 PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model .
    PD-1/PD-L1-IN-9
  • HY-P99242
    Alsevalimab
    1 Publications Verification

    		 CD276/B7-H3 Cancer
    Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
    Alsevalimab
  • HY-P99622
    Flanvotumab

    IMC-20D7S

    		 Tyrosinase Cancer
    Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
    Flanvotumab
  • HY-140696C
    m-PEG20000-OH

    mPEG20000-Hydroxy; Polyethylene glycol monomethyl ether 20000

    		 PROTAC Linkers Cancer
    m-PEG20000-OH can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Nanoscale micelles can be prepared by using amphiphilic block copolymers to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger activity in killing cancer cells than free Paclitaxel. And it preferentially accumulates in tumor tissue with only limited distribution in healthy organs.
    m-PEG20000-OH
  • HY-P10563
    Noraramtide

    BHV-1100

    		 CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-150212
    Tilsotolimod

    IMO-2125

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Tilsotolimod (IMO-2125) is a TLR9 agonist. Tilsotolimod activates the TLR9 signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod is applicable to research related to melanoma and colorectal cancer .
    Tilsotolimod
  • HY-150212A
    Tilsotolimod sodium

    IMO-2125 sodium

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Tilsotolimod (IMO-2125) sodium is a TLR9 agonist. Tilsotolimod sodium activates the TLR9 signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer .
    Tilsotolimod sodium
  • HY-P10696
    C16G2

    		Bacterial Infection
    C16G2 is a specific targeted antimicrobial peptide (STAMP) that targets the cariogenic oral pathogen Streptococcus mutans. C16G2 specifically recognizes and disrupts the bacterial cell membrane, causing small molecule leakage and loss of membrane potential, leading to bacterial killing. C16G2 exhibits higher selectivity and efficacy against Streptococcus mutans, unlike broad-spectrum antimicrobial peptides .
    C16G2
  • HY-P991708
    Olsutamig

    REGN-4336

    		 PSMA CD3 Cancer
    Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .
    Olsutamig
  • HY-P991671
    Anafiltamig

    JNJ-80948543

    		 CD3 CD20 Transmembrane Glycoprotein Cancer
    Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
    Anafiltamig
  • HY-132192A
    PD-1/PD-L1-IN-9 hydrochloride
    2 Publications Verification

    		 PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model .
    PD-1/PD-L1-IN-9 hydrochloride
  • HY-P991610
    S-095029

    Sym025

    		 C-type Lectin-like Receptors (CTLRs) Cancer
    S-095029 is a humanized IgG1 monoclonal antibody inhibitor targeting NKG2A. S-095029 significantly attenuates Fc-effector functions, inhibits the interaction with its ligand HLA-E, and increases the antibody-dependent cellular cytotoxicity mediated by other Fc-competent mAbs. S-095029 has a potent antitumor activity with enhancement of killing activity and cytokine secretion (IFNγ, TNF-α and CXCL9) of NK and γδ T-cells in co-culture with cancer cells .
    S-095029
  • HY-B0991R
    Amoxapine (Standard)

    CL-67772 (Standard)

    		 Reference Standards Autophagy Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Amoxapine (Standard) is the analytical standard of Amoxapine. This product is intended for research and analytical applications. Amoxapine (CL-67772) is a norepinephrine reuptake blocker and a 5-HT2/5-HT3 antagonist. Amoxapine can be used for the research of depression. Amoxapine has antibacterial activity. Amoxapine can enhance the killing effect of macrophages on mycobacterium by inducing autophagy, while protecting the cells from death .
    Amoxapine (Standard)
  • HY-169017
    MTT5

    		Toll-like Receptor (TLR) Cancer
    MTT5 is a toll-like receptor 7 (TLR7) agonist. MTT5 can couple with Deruxtecan (HY-13631E) and exert anti-tumor activity in HER2 positive solid tumors through tumor cell killing and immune activation .
    MTT5
  • HY-157975
    LM11

    		Glutaminase Cancer
    LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state .
    LM11
  • HY-178774
    IP-DNQ

    Isopentyl-deoxynboquinone

    		 Quinone Reductase Cancer
    IP-DNQ is an efficient NQO1 dependent cytotoxic agent. IP-DNQ has a potent killing effect on MCF-7 cells (IC50 = 0.18 µM). IP-DNQ can be used for cancer research .
    IP-DNQ
  • HY-P991514
    MIL62

    		CD20 Cancer
    MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
    MIL62
  • HY-178261
    KT53

    		Glutathione S-transferase Cancer
    KT53 is a highly active, selective, and cell penetrable GSTO1 inhibitor. KT53 can effectively inhibit GSTO1 activity in MDA-MB-435 (IC50 = 35 nM) cells. KT53 significantly enhances the killing effect of cisplatin (HY-17394) on MDA-MB-435 cancer cells. KT53 can be used for cancer research .
    KT53
  • HY-117422
    CAY10410

    11-Oxo-prosta-5Z,12E,14Z-trien-1-oic acid

    		 PPAR Cancer
    CAY10410 (11-Oxo-prosta-5Z), a 15d-PGJ2 analog, is a potent PPARγ agonist. CAY10410 has the ability to activate PPARγ in human B cells without killing B lymphocytes .
    CAY10410
  • HY-19605
    Gonyautoxin II

    		Sodium Channel Neurological Disease Cancer
    Gonyautoxin II is a paralytic shellfish poisoning toxin. Gonyautoxin II can block of the voltage-gated sodium channels at axonal level, impeding nerve impulse propagation. Gonyautoxin II has killing activity against mouse neuroblastoma cells. Gonyautoxin II can be used for the researches of cancer and neurological disease .
    Gonyautoxin II
  • HY-P11089
    TP53 neoepitope

    		MHC Cancer
    TP53 neoepitope is a high-affinity antigenic peptide targeting HLA-A. TP53 neoepitope can triggers CD8 + T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .
    TP53 neoepitope
  • HY-W011079
    5-Iodouridine
    1 Publications Verification

    		 Nucleoside Antimetabolite/Analog Infection Cancer
    5-Iodouridine is an iodine-containing pyrimidine nucleoside analog. 5-Iodouridine inhibits dihydroorotase with a Ki value of 340 µM. 5-Iodouridine significantly enhances the cell-killing effect of gamma irradiation. 5-Iodouridine can be used in the research of HSV-1 infection and leukemia .
    5-Iodouridine
  • HY-159123
    KHK-6

    		MAP4K Cancer
    KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
    KHK-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: